Investor Alert

New York Markets Open in:

Market Pulse Archives

Oct. 22, 2020, 10:35 a.m. EDT

Moderna's stock gains 3.5% after it completes enrollment in COVID-19 vaccine trial

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Moderna Inc. (MRNA)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Moderna Inc. /zigman2/quotes/205619834/composite MRNA +20.24% gained 3.5% in trading on Thursday after it said it has completed enrollment of 30,000 participants in the Phase 3 clinical trial for its COVID-19 vaccine candidate. The trial is being conducted in partnership with the National Institutes of Health and the Biomedical Advanced Research and Development Authority. The preclinical company also said that 25,650 participants have received their second and final dose of the experimental vaccine in the late-stage trial, and about one-third of the total number of participants are people of color. Ensuring equitable representation in the coronavirus vaccine trials is an increasingly growing concern for some health care providers given the disproportionate impact of the virus on minorities in the U.S. Moderna's stock has soared 262.1% so far this year. The S&P 500 /zigman2/quotes/210599714/realtime SPX -0.46% , in comparison, is up 6.3%.

US : U.S.: Nasdaq
$ 152.74
+25.71 +20.24%
Volume: 73.20M
Nov. 30, 2020 4:00p
P/E Ratio
Dividend Yield
Market Cap
$50.27 billion
Rev. per Employee
-16.72 -0.46%
Volume: 3.65B
Nov. 30, 2020 5:34p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.